Comparing Tuberculosis Diagnostic Yield in Smear/Culture and Xpert® MTB/RIF-Based Algorithms Using a Non-Randomised Stepped-Wedge Design
Pren Naidoo, Rory Dunbar, Carl Lombard, Elizabeth du Toit, Judy Caldwell, Anne Detjen, S Bertel Squire, Donald A Enarson, Nulda Beyers, Pren Naidoo, Rory Dunbar, Carl Lombard, Elizabeth du Toit, Judy Caldwell, Anne Detjen, S Bertel Squire, Donald A Enarson, Nulda Beyers
Abstract
Setting: Primary health services in Cape Town, South Africa.
Study aim: To compare tuberculosis (TB) diagnostic yield in an existing smear/culture-based and a newly introduced Xpert® MTB/RIF-based algorithm.
Methods: TB diagnostic yield (the proportion of presumptive TB cases with a laboratory diagnosis of TB) was assessed using a non-randomised stepped-wedge design as sites transitioned to the Xpert® based algorithm. We identified the full sequence of sputum tests recorded in the electronic laboratory database for presumptive TB cases from 60 primary health sites during seven one-month time-points, six months apart. Differences in TB yield and temporal trends were estimated using a binomial regression model.
Results: TB yield was 20.9% (95% CI 19.9% to 22.0%) in the smear/culture-based algorithm compared to 17.9% (95%CI 16.4% to 19.5%) in the Xpert® based algorithm. There was a decline in TB yield over time with a mean risk difference of -0.9% (95% CI -1.2% to -0.6%) (p<0.001) per time-point. When estimates were adjusted for the temporal trend, TB yield was 19.1% (95% CI 17.6% to 20.5%) in the smear/culture-based algorithm compared to 19.3% (95% CI 17.7% to 20.9%) in the Xpert® based algorithm with a risk difference of 0.3% (95% CI -1.8% to 2.3%) (p = 0.796). Culture tests were undertaken for 35.5% of smear-negative compared to 17.9% of Xpert® negative low MDR-TB risk cases and for 82.6% of smear-negative compared to 40.5% of Xpert® negative high MDR-TB risk cases in respective algorithms.
Conclusion: Introduction of an Xpert® based algorithm did not produce the expected increase in TB diagnostic yield. Studies are required to assess whether improving adherence to the Xpert® negative algorithm for HIV-infected individuals will increase yield. In light of the high cost of Xpert®, a review of its role as a screening test for all presumptive TB cases may be warranted.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- World Health Organisation. Global Tuberculosis Report 2013. 2013.
- World Health Organisation. Automated Real-time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB / RIF System. Policy Statement. 2011.
- Meyer-Rath G, Schnippel K, Long L, MacLeod W, Sanne I, Stevens W, et al. The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One. 2012;7(5):e36966 Available from: [cited 2013 Feb 28] 10.1371/journal.pone.0036966
- Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, Pai M DN. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults (Review). Cochrane Collaboration. 2013;(1). Available from: [cited 2013 Aug 11]
- Mase SR, Ramsay A, Ng V, Henry M, Hopewell PC, Cunningham J, et al. Yield of serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis. 2007;11(5):485–95.
- Steingart KR, Henry M, Ng V, Hopewell PC, Ramsay A, Cunningham J, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006;6(9):570–81.
- Getahun H, Harrington M, O’Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet. 2007;369(9578):2042–9.
- Reid MJA, Shah NS. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect Dis. 2009;9(3):173–84. 10.1016/S1473-3099(09)70043-X
- Perkins MD, Cunningham J. Facing the crisis: improving the diagnosis of tuberculosis in the HIV era. J Infect Dis. 2007;196 Suppl S15–27.
- Dowdy DW, Brien MAO, Bishai D. Cost-effectiveness of novel diagnostic tools for the diagnosis. Int J Tuberc Lung Dis. 2008;12(9):1021–9.
- Shah M, Chihota V, Coetzee G, Churchyard G, Dorman SE. Comparison of laboratory costs of rapid molecular tests and conventional diagnostics for detection of tuberculosis and drug-resistant tuberculosis in South Africa. BMC Infect Dis. 2013;13(1):352 Available from: [cited 2014 Jan 29]
- Statistics South Africa. Statistical release Mid-year population estimates. 2014.
- Steingart KR, Ng V, Henry M, Hopewell PC, Ramsay A, Cunningham J, et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006;6(10):664–74.
- Van Den Handel T, Hampton KH, Sanne I, Stevens W, Crous R, Van Rie A. The impact of Xpert® MTB / RIF in sparsely populated rural settings. Int J Tuberc Lung Dis. 2015;19:392–8. 10.5588/ijtld.14.0653
- Mupfumi L, Makamure B, Chirehwa M, Sagonda T, Zinyowera S, Mason P, et al. Impact of Xpert MTB / RIF on Antiretroviral Therapy-Associated Tuberculosis and Mortality: A Pragmatic Randomized Controlled Trial. Open forum infectious diseases. 2014; 1 (1): ofu038 (1–8). Available from [cited 2015 March 20] 10.1093/ofid/ofu038
- Lawn SD, Brooks S V, Kranzer K, Nicol MP, Whitelaw A, Vogt M, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med. 2011;8(7):e1001067 Available from: [cited 2014 Aug 13] 10.1371/journal.pmed.1001067
- Cobelens F, van den Hof S, Pai M, Squire SB, Ramsay A, Kimerling ME. Which new diagnostics for tuberculosis, and when? J Infect Dis. 2012;205 Suppl S191–8.
- Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. 2011;377(9776):1495–505. 10.1016/S0140-6736(11)60438-8
- Sachdeva KS, Raizada N, Sreenivas A, Van’t Hoog AH, van den Hof S, Dewan PK, et al. Use of Xpert MTB/RIF in Decentralized Public Health Settings and Its Effect on Pulmonary TB and DR-TB Case Finding in India. PLoS One. 2015;10(5):e0126065 Available from: [cited 2015 May 28] 10.1371/journal.pone.0126065
- Durovni B, Saraceni V, van den Hof S, Trajman A, Cordeiro-Santos M, Cavalcante S, et al. Impact of Replacing Smear Microscopy with Xpert MTB/RIF for Diagnosing Tuberculosis in Brazil: A Stepped-Wedge Cluster-Randomized Trial. PLoS Med. 2014. December;11(12):e1001766 Available from: [cited 2014 Dec 10] 10.1371/journal.pmed.1001766
- Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet. 2013;383(9915):424–35. 10.1016/S0140-6736(13)62073-5
- Middelkoop K, Bekker L-G, Myer L, Whitelaw A, Grant A, Kaplan G, et al. Antiretroviral program associated with reduction in untreated prevalent tuberculosis in a South African township. Am J Respir Crit Care Med. 2010;182(8):1080–5. 10.1164/rccm.201004-0598OC
- Nanoo A, Izu A, Ismail NA, Ihekweazu C, Abubakar I, Mametja D, et al. Articles Nationwide and regional incidence of microbiologically confi rmed pulmonary tuberculosis in South Africa, 2004–12 : a time series analysis. Lancet Infect Dis. 2015;3099(15):1–11.
- Langley I, Lin H-H, Egwaga S, Doulla B, Ku C-C, Murray M, et al. Assessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrated modelling approach. Lancet Glob Heal. 2014;2(10):e581–91. Available from: [cited 2015 Jun 5]
- Langley I, Doulla B, Lin H-H, Millington K, Squire B. Modelling the impacts of new diagnostic tools for tuberculosis in developing countries to enhance policy decisions. Health Care Manag Sci. 2012;15(3):239–53. 10.1007/s10729-012-9201-3
- Brown CA, Lilford RJ. The stepped wedge trial design: a systematic review. BMC Med Res Methodol. 2006. 6:54 Available from: [cited 2014 Feb 19]
- Theron G, Peter J, Dowdy D, Langley I, Squire SB, Dheda K. Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings? Lancet Infect Dis. 2014;14(6):527–32. 10.1016/S1473-3099(13)70360-8
- Cox HS, Mbhele S, Mohess N, Whitelaw A, Muller O, Zemanay W, et al. Impact of Xpert MTB / RIF for TB Diagnosis in a Primary Care Clinic with High TB and HIV Prevalence in South Africa: A Pragmatic Randomised Trial. Plos Med. 2014;11(11):1–12. 10.1371/journal.pmed.1001760 [cited 2014 Nov 30]
- Naidoo P, du Toit E, Dunbar R, Lombard C, Caldwell J, Detjen A, et al. A Comparison of Multidrug-Resistant Tuberculosis Treatment Commencement Times in MDRTBPlus Line Probe Assay and Xpert® MTB/RIF-Based Algorithms in a Routine Operational Setting in Cape Town. PLoS One. 2014;9(7):e103328 Available from: [cited 2014 Aug 1] 10.1371/journal.pone.0103328
- Cox HS, Daniels JF, Muller O, Nicol MP, Cox V, Van Cutsem G, et al. Impact of Decentralized Care and the Xpert MTB / RIF Test on Rifampicin-Resistant Tuberculosis Treatment Initiation in Khayelitsha, South Africa. Open Forum Infectious Diseases. 2015;2(1):ofv014). Available from: [cited 2015 Jun 9] 10.1093/ofid/ofv014
- Toit E, Squire SB, Dunbar R, Machekano R, Madan J, Beyers N, et al. Comparing multidrug-resistant tuberculosis patient costs under molecular diagnostic algorithms in South Africa. Int J Tuberc Lung Dis.2015;19(8):960–968. 10.5588/ijtld.14.0703
- Vassall A, van Kampen S, Sohn H, Michael JS, John KR, den Boon S, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med. 2011. November;8(11):e1001120 Available from: [cited 2014 Jan 29] 10.1371/journal.pmed.1001120
- Churchyard G, McCarthy K, Fielding KL, Stevens W, Chihota V, Nicol M, et al. Effect of Xpert MTB / RIF On Early Mortality in Adults With Suspected TB: A Pragmatic Randomized Trial. CROI. 2014; Abstract.
Source: PubMed